Swiss National Bank
PRQR icon

Swiss National Bank’s ProQR Therapeutics PRQR Stock Holding History

Swiss National Bank’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-51,100
Closed -$294K – 2529
2019
Q3 		$294K Buy
51,100
+2,000
+4% +$16K ﹤0.01% 2458
2019
Q2 		$447K Buy
49,100
+2,500
+5% +$29.5K ﹤0.01% 2447
2019
Q1 		$646K Hold
46,600
– – ﹤0.01% 2286
2018
Q4 		$735K Buy
+46,600
New +$855K ﹤0.01% 2173

Other funds holding PRQR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Swiss National Bank's PRQR Position: Q4 2019 in Review

Swiss National Bank sold out of ProQR Therapeutics (PRQR) in Q4 2019, closing a stake of 51,100 shares — an estimated $294K sold.

Swiss National Bank first reported a position in PRQR in Q4 2018 and held it in 4 quarters. The position peaked at $735K in Q4 2018. 51 funds tracked by Wall St. Rank hold PRQR as of Q4 2019.

  • Swiss National Bank reported no remaining ProQR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Swiss National Bank sold 51,100 ProQR Therapeutics shares in Q4 2019, an estimated $294K.
  • Swiss National Bank first reported a position in ProQR Therapeutics in Q4 2018 and held it in 4 quarters.
  • Swiss National Bank's ProQR Therapeutics position peaked at $735K in Q4 2018.
  • 51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2019.

Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.